Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/18912
Title: Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells.
Austin Authors: Gan, Hui K ;van den Bent, Martin;Lassman, Andrew B;Reardon, David A;Scott, Andrew M 
Affiliation: Brain Tumour Centre, Erasmus MC Cancer Institute, Groene Hilledijk 301, 3075 EA Rotterdam, Netherlands
Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana 2134, Boston, Massachusetts 02215, USA
La Trobe University School of Cancer Medicine, 145 Studley Road, Heidelberg, Victoria 3084, Australia
Department of Medicine, University of Melbourne, 145 Studley Road, Heidelberg, Victoria 3084, Australia
Department of Neurology & Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, 161 Fort Washington Avenue, New York, New York 10032, USA
Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
Austin Health, Heidelberg, Victoria, Australia
Issue Date: Nov-2017
metadata.dc.date: 2017-07-04
Publication information: Nature reviews. Clinical oncology 2017; 14(11): 695-707
Abstract: Glioblastomas are high-grade brain tumours with a poor prognosis and, currently, few available therapeutic options. This lack of effective treatments has been linked to diverse factors, including target selection, tumour heterogeneity and poor penetrance of therapeutic agents through the blood-brain barrier and into tumours. Therapies using monoclonal antibodies, alone or linked to cytotoxic payloads, have proved beneficial for patients with different solid tumours; these approaches are currently being explored in patients with glioblastoma. In this Review, we summarise clinical data regarding antibody-drug conjugates (ADCs) against a variety of targets in glioblastoma, and compare the efficacy and toxicity of targeting EGFR with ADCs versus naked antibodies in order to illustrate key aspects of the use of ADCs in this malignancy. Finally, we discuss the complex challenges related to the biology and mutational changes of glioblastoma that can affect the use of ADC-based therapies in patients with this disease, and highlight potential strategies to improve efficacy.
URI: http://ahro.austin.org.au/austinjspui/handle/1/18912
DOI: 10.1038/nrclinonc.2017.95
ORCID: 0000-0002-6656-295X
PubMed URL: 28675164
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.